DEMI-REGROTON
LOE ApproachingNDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMI-REGROTON is an oral tablet small-molecule NDA approved in 1964 by Sanofi; mechanism of action and specific indications are not publicly detailed in available data. The product represents a legacy therapeutic from the mid-20th century and is approaching loss of exclusivity.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), this product is in defensive positioning; team focus shifts toward cost management and volume retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DEMI-REGROTON offers minimal active career momentum; zero linked job openings signal either niche internal ownership or phase-out planning. Roles available typically focus on managing decline, ensuring regulatory compliance, and protecting residual market share rather than innovation or growth.
Brand Manager (Legacy Products)Commercial Operations Analyst
Worked on DEMI-REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.